Accepted for Publication: July 1, 2011.
Published Online: January 9, 2012. doi:10.1001/archneurol.2011.845
Author Contributions:Study concept and design: Head and Bugg. Acquisition of data: Head, Bugg, Goate, Fagan, Mintun, Benzinger, and Morris. Analysis and interpretation of data: Head, Bugg, Mintun, and Holtzman. Drafting of the manuscript: Head and Bugg. Critical revision of the manuscript for important intellectual content: Head, Bugg, Goate, Fagan, Mintun, Benzinger, Holtzman, and Morris. Obtained funding: Goate, Holtzman, and Morris. Administrative, technical, and material support: Head, Fagan, Mintun, Benzinger, and Morris. Study supervision: Goate, Holtzman, and Morris.
Financial Disclosure: Dr Goate reports that she has received consultancy fees from AstraZeneca, has provided expert testimony to Howrey & Associates, and has received payment for lectures, including service on speakers bureaus, from Pfizer, AstraZeneca, and Genentech and royalties from Taconic, and that her institution has received grants from AstraZeneca, Genentech, and Pfizer. Dr Holtzman reports that he has consulted for Pfizer, Bristol-Myers Squibb, Innogenetics, and Medtronic and is on the scientific advisory boards of EnVivo, Satori, and C2N Diagnostics and that he has received research grants from AstraZeneca, Eli Lilly, and C2N Diagnostics.
Funding/Support: This work was supported by National Institutes of Health grants P50 AG05861, P01 AG03991, and P01 AG026276. Dr Bugg was supported by National Institute on Aging grant 5T32AG00030.
Additional Contributions: We thank our lumbar puncture physicians for obtaining CSF samples, Ms Aarti Shah and Mr Matt Amos for processing and analyzing the CSF samples, and Ms Sushila Sathyan for scheduling the lumbar punctures. We thank the Knight Alzheimer’s Disease Research Center Genetics Core for APOE genotyping.